{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:33:43Z","timestamp":1786991623357,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T00:00:00Z","timestamp":1738454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jcf.2025.02.002","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T23:39:36Z","timestamp":1738712376000},"page":"284-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world outcomes of generic elexacaftor\/tezacaftor\/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI, modulator-sparing strategies to reduce cost"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-6137","authenticated-orcid":false,"given":"Marco","family":"Zampoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1148-4747","authenticated-orcid":false,"given":"Janine","family":"Verstraete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8588-5250","authenticated-orcid":false,"given":"Tony","family":"Biebuyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Calligaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Coetzee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Els","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlize","family":"Frauendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gebers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanri","family":"Truter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.02.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.26954","article-title":"International disparities in diagnosis and treatment access for cystic fibrosis","author":"Guo","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.02.002_bib0002","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: The changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front Pharmacol"},{"issue":"10408","key":"10.1016\/j.jcf.2025.02.002_bib0003","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2025.02.002_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.chpulm.2024.100077","article-title":"A dramatic decline in lung transplantation for cystic fibrosis in the United States","author":"Milinic","year":"2024","journal-title":"CHEST Pulm"},{"key":"10.1016\/j.jcf.2025.02.002_bib0005","article-title":"Impact of discontinuing both hypertonic saline and Dornase alfa after elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis","author":"Mayer-Hamblett","year":"2025","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.jcf.2025.02.002_bib0006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.02.002_bib0007","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcf.2024.02.014","article-title":"A contemporary assessment of CFTR modulator use and eligibility","volume":"23","author":"Rubin","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.02.002_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1163391","article-title":"Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap!","volume":"14","author":"Zampoli","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2025.02.002_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor\u2013tezacaftor\u2013ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.02.002_bib0010","unstructured":"Zampoli M., Verstraete J., Fraeundorf M., CF Steering Committee. South African cystic fibrosis registry 2021 annual report; available at: https:\/\/sacfa.org.za\/registry-annual-report-2021\/; accessed 30 June 2023."},{"key":"10.1016\/j.jcf.2025.02.002_bib0011","unstructured":"Food and Drug Administration 2021, Trikafta; avaialble at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s008lbl.pdf; accessed 30 June 2023."},{"issue":"9","key":"10.1016\/j.jcf.2025.02.002_bib0012","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1164\/rccm.202307-1200VP","article-title":"Affordable CFTR modulator drugs for cystic fibrosis: all CF lives worldwide matter!","volume":"208","author":"Zampoli","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2025.02.002_bib0013","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.jcf.2025.02.002_bib0014","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJM199509073331004","article-title":"Ketoconazole to reduce the need for cyclosporine after cardiac transplantation","volume":"333","author":"Keogh","year":"1995","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jcf.2025.02.002_bib0015","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3855\/jidc.19202","article-title":"Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2024","journal-title":"J Infect Dev Ctries"},{"issue":"7","key":"10.1016\/j.jcf.2025.02.002_bib0016","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1016\/S2352-3018(24)00089-4","volume":"11","author":"Matthews","year":"2024","journal-title":"Lancet HIV"},{"issue":"7","key":"10.1016\/j.jcf.2025.02.002_bib0017","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/phar.2703","article-title":"Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir\/ritonavir with rifampin in pediatric patients","volume":"43","author":"Salerno","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.jcf.2025.02.002_bib0018","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/cpt.3214","article-title":"Pharmacokinetic enhancement of elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis: a cost reduction strategy to address global disparities in access","volume":"115","author":"Hong","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.jcf.2025.02.002_bib0019","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1164\/rccm.201402-0385CI","article-title":"Macrolide antibiotics and the risk of cardiac arrhythmias","volume":"189","author":"Albert","year":"2014","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:36:56Z","timestamp":1777333016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325000517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1569199325000517"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.02.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of generic elexacaftor\/tezacaftor\/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI, modulator-sparing strategies to reduce cost","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}